Other analysts have also recently issued research reports about the company. Baader Bank set a €140.00 ($166.67) price objective on Bayer and gave the stock a buy rating in a research report on Thursday, September 28th. BNP Paribas set a €130.00 ($154.76) price objective on Bayer and gave the stock a buy rating in a research report on Monday, September 25th. Warburg Research set a €121.00 ($144.05) target price on Bayer and gave the stock a buy rating in a research note on Wednesday, September 20th. Sanford C. Bernstein set a €129.00 ($153.57) target price on Bayer and gave the stock a buy rating in a research note on Friday, October 13th. Finally, equinet set a €118.00 ($140.48) target price on Bayer and gave the stock a buy rating in a research note on Friday, October 13th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the company. Bayer presently has an average rating of Buy and an average price target of €121.67 ($144.84).
Bayer (BAYN) traded down €0.12 ($0.14) during trading on Wednesday, hitting €103.48 ($123.19). The stock had a trading volume of 2,174,508 shares. The firm has a market cap of $85,470.00 and a PE ratio of 27.74. Bayer has a 52-week low of €100.60 ($119.76) and a 52-week high of €123.82 ($147.40).
TRADEMARK VIOLATION WARNING: This news story was published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3144697/citigroup-reiterates-buy-rating-for-bayer-bayn.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women?s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.